obesity

News

23andMe study explains variable results with obesity drugs

Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.

Patients

Reframing obesity beyond stigma and simplicity

Deep Dive editor Eloise McLennan reports on Novo Nordisk's inaugural Weight Talks Summit in London.

News

Lilly bags FDA okay for Wegovy pill rival orforglipron

Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.

News

Obesity-focused biotech Kailera joins IPO queue in US

Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.

News

Wave's stock wavers on obesity drug data

Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don't seem to agree.

News

Novo unveils first data for 'triple G' agonist in diabetes

Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.

23andMe study explains variable results with obesity drugs

Reframing obesity beyond stigma and simplicity

Lilly bags FDA okay for Wegovy pill rival orforglipron

Obesity-focused biotech Kailera joins IPO queue in US

Wave's stock wavers on obesity drug data

Novo unveils first data for 'triple G' agonist in diabetes

Chinese trial backs base-editing drug for thalassaemia

Using AI-driven synthetic personas to take your insights fur...

obesity

Editor's Picks